Skip to main content
. 2014 Sep 21;2014:437971. doi: 10.1155/2014/437971

Table 3.

Calculated age-specific incidence rates, crude rates, and ASR (World), males, Egypt 2008–2011.

Site 0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75+ Crude rate ASR %
Lip 0.5 0.3 0.8 1.4 0.6 1.8 8.7 1.5 0.3 0.4 0.23%
Tongue 0.3 1.4 1.3 3.1 1.9 1.8 2.2 0.3 0.5 0.27%
Mouth 0.1 0.2 0.5 0.8 1.5 2.5 4.6 0.6 2.6 1.4 0.5 0.6 0.41%
Salivary glands 0.1 0.1 0.2 0.7 1.4 2.0 2.6 4.5 5.2 0.3 0.5 0.25%
Tonsil 0.3 0.01%
Other oropharynx 0.1 0.4 0.6 0.8 2.8 0.1 0.1 0.07%
Nasopharynx 0.3 0.2 3.4 0.4 3.6 5.2 0.3 0.4 0.26%
Hypopharynx 0.1 0.3 0.9 1.4 0.6 1.4 1.5 0.2 0.2 0.13%
Pharynx unspec. 0.2 1.0 1.5 0.1 0.1 0.07%
Esophagus 0.3 0.2 0.3 1.4 1.8 6.1 4.1 11.2 10.8 24.4 14.7 1.4 2.3 1.20%
Stomach 0.1 0.1 0.3 0.2 0.7 0.5 2.0 2.6 5.0 6.0 11.9 6.4 21.5 14.1 1.5 2.3 1.26%
Small intestine 0.1 0.5 0.5 0.6 0.3 0.4 1.4 0.8 1.5 0.2 0.3 0.17%
Colon 0.1 0.3 0.7 2.1 2.5 1.9 6.5 14.2 11.0 19.8 18.9 31.5 32.6 3.1 4.7 2.63%
Rectum 0.1 0.7 1.2 0.7 1.2 2.2 2.0 3.4 4.1 3.4 2.6 8.7 1.5 1.0 1.3 0.84%
Anus 0.3 0.5 0.5 0.6 0.6 2.1 2.0 1.0 0.3 0.3 0.24%
Liver 0.3 0.4 0.4 0.2 0.3 1.3 1.4 6.1 21.2 76.3 174.2 258.7 323.1 313.8 327.1 363.5 39.5 61.8 33.63%
Gallbladder and so forth 0.4 0.5 0.6 0.6 1.0 1.0 5.9 1.0 4.7 7.4 0.5 0.7 0.40%
Pancreas 1.3 0.2 2.5 7.7 9.0 14.9 25.3 26.4 12.7 19.3 2.7 4.2 2.31%
Nose, sinuses and so forth 0.1 0.5 0.3 1.2 1.4 8.2 0.2 0.3 0.17%
Larynx 0.2 2.1 2.6 6.6 6.8 18.2 11.0 23.2 32.5 1.9 3.1 1.58%
Trachea, Bronchus, Lung 0.1 0.1 0.4 0.8 1.2 1.2 3.0 3.8 12.5 19.3 39.1 49.0 49.3 73.9 76.1 6.7 10.4 5.69%
Other Thoracic organs 0.3 0.1 0.2 0.2 0.6 1.2 2.8 3.5 3.2 7.1 9.8 8.9 0.8 1.2 0.65%
Bone 0.1 1.2 1.4 0.7 1.8 0.8 1.0 1.0 1.4 2.0 4.2 3.7 13.9 8.6 8.4 15.6 1.9 2.5 1.62%
Melanoma of skin 0.1 0.2 0.6 0.4 1.8 2.8 0.1 0.2 0.11%
Other skin 0.6 0.1 0.3 0.4 0.5 0.5 1.1 0.6 3.2 4.5 14.0 14.2 18.5 30.4 1.6 2.6 1.35%
Mesothelioma 0.8 0.5 1.4 0.8 0.1 0.2 0.10%
Kaposi sarcoma 0.2 1.1 1.3 0.8 1.4 0.1 0.2 0.10%
Connective, Soft tissue 0.3 0.1 0.1 0.6 1.1 2.0 1.3 1.3 3.1 3.5 3.6 8.3 4.6 6.1 18.8 2.2 1.7 2.2 1.47%
Breast 0.4 0.3 2.2 0.3 2.5 3.1 3.4 3.6 2.8 5.9 0.6 0.9 0.51%
Penis 0.00%
Prostate 0.2 0.3 0.3 1.3 4.1 11.2 24.6 47.5 90.3 216.5 5.0 9.3 4.27%
Testis 0.1 1.1 1.2 0.7 1.5 0.6 0.6 0.4 0.4 0.6 1.4 2.2 0.5 0.5 0.43%
Other male genital 0.4 0.8 1.4 0.1 0.04%
Kidney 1.2 0.1 0.2 0.2 0.5 0.5 3.4 6.9 9.8 7.9 16.9 14.1 22.3 1.8 2.7 1.53%
Renal pelvis 0.1 0.2 0.6 0.3 0.4 1.9 2.0 1.8 2.8 4.4 0.3 0.4 0.25%
Ureter 1.4 3.0 0.1 0.04%
Bladder 0.1 0.1 0.3 0.1 1.2 1.7 2.2 4.0 9.2 28.7 68.4 97.2 128.6 194.8 205.6 12.6 21.1 10.71%
Other urinary organs 0.6 0.01%
Eye 0.5 0.3 0.4 0.4 1.8 0.6 0.2 0.2 0.16%
Brain, Nervous tissue 2.9 3.0 1.8 1.7 1.5 3.3 4.2 6.8 7.3 7.3 15.5 14.5 27.2 30.4 46.7 91.4 6.4 9.0 5.48%
Thyroid 0.2 0.8 1.2 1.9 1.1 3.2 4.5 4.3 6.6 8.7 3.0 1.1 1.5 0.95%
Adrenal gland 0.3 0.1 0.6 0.8 1.4 0.1 0.1 0.08%
Other endocrine 0.5 0.1 0.3 0.5 0.3 1.0 0.4 1.3 0.6 2.8 0.3 0.4 0.25%
Hodgkin disease 0.5 1.7 1.7 1.5 1.5 1.4 0.2 1.7 2.5 2.0 1.4 5.3 6.1 2.8 1.5 1.5 1.7 1.29%
Non-Hodgkin lymphoma 1.1 1.2 1.5 1.0 2.2 2.5 2.1 3.6 5.8 16.6 24.4 36.0 33.8 29.5 38.1 28.8 6.4 8.8 5.48%
Immunoproliferative dis. 0.00%
Multiple myeloma 0.5 0.5 1.1 0.4 3.1 3.9 8.0 0.8 2.8 2.9 0.6 0.9 0.53%
Lymphoid leukemia 3.9 2.2 0.7 0.2 1.4 0.7 1.5 1.1 1.8 1.5 5.0 6.0 8.9 5.6 1.8 2.1 1.50%
Myeloid Leukemia 0.8 0.4 0.3 0.8 1.0 0.4 1.1 0.7 1.4 1.8 4.2 3.3 3.4 2.6 4.5 1.5 1.1 1.3 0.96%
Leukemia unspec. 1.0 1.2 1.1 0.6 2.1 2.2 1.7 0.5 2.1 4.7 1.8 6.0 8.0 3.5 7.3 20.8 2.1 2.6 1.80%
Other & unspecified 2.4 2.8 0.9 1.7 1.3 1.8 3.3 3.1 6.1 15.0 22.9 25.2 44.9 54.7 64.7 83.6 7.6 11.2 6.52%

All sites Total 17.1 15.4 10.5 10.5 20.1 23.9 30.6 42.8 83.8 195.4 389.6 582.4 793.5 840.2 1096.1 1335.6 117.3 178.5 100.00%
All sites but C44# 16.6 15.4 10.4 10.5 19.8 23.5 30.0 42.4 82.7 194.9 386.4 577.9 779.5 826.0 1077.5 1305.3 115.7 175.9 98.65%

#Incidence rates do not include nonmelanoma skin cancer.

HHS Vulnerability Disclosure